Metabolism of the failing heart and the impact of SGLT2 inhibitors

References

• Kolwicz SJ, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113:603–616.
   Google Scholar
• Wende AR, Brahma MK, McGinnis GR, et al. Metabolic origins of heart failure. JACC Basic to Transl Sci. 2017;2:297–310.
   Google Scholar
• Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). developed with the special contribution. Eur Hear J. 2016;37:2129–2200.
   Google Scholar
• Noordali H, Loudon BL, Frenneaux MP, et al. Cardiac metabolism — a promising therapeutic target for heart failure. Pharmacol Ther.[Internet]. 2018;182:95–114.
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. [Internet]. 2015;373:2117–2128. Available from. http://www.nejm.org/doi/10.1056/NEJMoa1504720
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canvas. N Engl J Med. Internet]. 2017;377:644–657.
   Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. Internet]. 2018;NEJMoa1812389.
   Google Scholar
• Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267–1274.
   Google Scholar
• Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond atp production. Circ Res. 2013;113:709–724.
   Google Scholar
• Van Der Vusse GJ, Van Bilsen M, Glatz JFC. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45:279–293.
   Google Scholar
• Depre C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578–588.
   Google Scholar
• Chatham JC. Lactate - the forgotten fuel! J Physiol. 2002;542:333.
   Google Scholar
• Lloyd S, Brocks C, Chatham JC. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Circ Physiol. 2015;285:H163–H172.
   Google Scholar
• Labarthe F, Petrof BJ, Bouchard B, et al. Profiling substrate fluxes in the isolated working mouse heart using 13 C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am J Physiol Circ Physiol. 2004;286:H1461–H1470.
   Google Scholar
• Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. AJP Hear Circ Physiol. Internet]. 2013;304:H1060–H1076.
   Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
   Google Scholar
• Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Texas Hear Inst J. Internet]. 2011;38:533–538. Available from http://www.ncbi.nlm.nih.gov/pubmed/22163128%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3231554
   Google Scholar
• Russell RR, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991;87:384–390.
   Google Scholar
• Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. Internet]. 2018;15:457–470.
   Google Scholar
• Stanley W, Recchia F, Lopaschuk G. Myocardial substrate metabolism in the normal and failing heart. Review Physiol Rev. 2005;85:1093–1129.
   Google Scholar
• Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fat Acids. 2004;70:309–319.
   Google Scholar
• Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A thrifty substrate hypothesis. Diabetes Care. 2016;39:1108–1114.
   Google Scholar
• Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab. Internet]. 2016;24:200–202.
   Google Scholar
• Kolwicz SJ, Olson D, Marney L, et al. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728–738.
   Google Scholar
• Maack C, Lehrke M, Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the translational research committee of the heart failure association–European society of cardiology. Eur Heart J. Internet]. 2018;31:1–15.
   Google Scholar
• Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet.Internet]. 1963;281:785–789.
   Google Scholar
• Pierpont GL, Jones B, Traverse JH, et al. Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. Circ Res. 2012;84:401–408.
   Google Scholar
• Mansoor AM, Murakami Y, From AHL, et al. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Circulation. 2012;99:942–948.
   Google Scholar
• Zhou Y-T, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci. Internet]. 2000;97:1784–1789.
   Google Scholar
• Johnson BF, Nesto RW, Pfeifer MA, et al. Cardiac abnormalities in diabetic patients with neuropathy. Diabetes Care. 2004;27:448–454.
   Google Scholar
• Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol.Internet]. 1997;30:527–532.
   Google Scholar
• Shen W, Asai K, Uechi M, et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation. 1999;100:2113–2118.
   Google Scholar
• Rc S, Df H, Ra A. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem. 1998;180:171–177.
   Google Scholar
• Ingwall JS, Weiss RG. Is the failing heart energy starved? on using chemical energy to support cardiac function. Circ Res. 2004;95:135–145.
   Google Scholar
• Bittls JA, Ingwall J. Reaction rates of creatine kinase and atp synthesis in the isolated rat heart. J Biol Chem. 1985;260:3512–3517.
   Google Scholar
• Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698–705.
   Google Scholar
• ME Y HT,PM. Adaptation and aladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105:1727–1733.
   Google Scholar
• Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146:5341–5349.
   Google Scholar
• Abdurrachim D, Nabben M, Hoerr V, et al. Diabetic db/db mice do not develop heart failure upon pressure overload: A longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations. Cardiovasc Res. 2017;113:1148–1160.
   Google Scholar
• Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. Internet]. 2018;14(12):1287–1302.
   Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
   Google Scholar
• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. Internet]. 2017;13:11–26.
   Google Scholar
• Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328.
   Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab.Internet]. 2016;18:783–794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27059700
   Google Scholar
• Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group HG. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–828.
   Google Scholar
• Cherney DZI, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:1–8.
   Google Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–1193.
   Google Scholar
• Kimura G. Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J. Internet]. 2016;80:2277–2281. Available from: https://www.jstage.jst.go.jp/article/circj/80/11/80_CJ-16-0780/_article
   Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.[Erratum appears in J Clin Invest. 2014 Apr 1;124(4):1868]. J Clin Invest. 2014;124:499–508.
   Google Scholar
• Fitchett D, Butler J, Van De Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEVRtrial. Eur Heart J. 2018;39:363–370.
   Google Scholar
• Santos-Gallego CG, Ibanez JAR, Antonio RS, et al. Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility. J Am Coll Cardiol. Internet]. 2018;71:A674. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109718312154
   Google Scholar
• SantosGallego C, Requena-Ibanez J, Antonio RS, et al. Infusion of the ketone body β-hydroxybutyrate improves left ventricular systolic function in an animal model of heart failure with reduced ejection fraction. AHA Abstract. 2018;138.
   Google Scholar
• Verma S, Wagg CS, Uddin GM, et al. Empagliflozin increases cardiac energy production in diabetes. JACC Basic to Transl Sci. 2018;3:575–587.
   Google Scholar
• Abdurrachim D, Teo XQ, Woo CC, et al. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized 13C magnetic resonance spectroscopy study. Diabetes Obes Metab. 2019;21:357–365.
   Google Scholar
• Cahill GF Jr, Veech RL. Ketoacids? Good Medicine? Trans Am Clin Climatol Assoc. 2003;114:149–161.
   Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1196.
   Google Scholar
• Inagaki N, Goda M, Yokota S, et al. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother.Internet]. 2015;16:1577–1591. Available from: http://www.tandfonline.com/doi/full/10.1517/14656566.2015.1055250
   Google Scholar
• Schugar RC, Moll AR, André d’Avignon D, et al. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab. 2014;3:754–769.
   Google Scholar
• Best TH, Franz DN, Gilbert DL, et al. Cardiac complications in pediatric patients on the ketogenic diet. Neurology. 2000;54(12):2328-2330.
   Google Scholar
• Packer M. Activationand inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation. 2017;136:1548–1559.
   Google Scholar
• Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+exchanger, lowering of cytosolic Na+and vasodilation. Diabetologia. 2018;61:722–726.
   Google Scholar
• Baartscheer A, Schumacher CA, Rci W, et al. Empagliflozin decreases myocardial cytoplasmic Na+through inhibition of the cardiac Na+/H+exchanger in rats and rabbits. Diabetologia. 2017;60:568–573.
   Google Scholar
• Prasad V, Lorenz J, Miller M, et al. Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress. J Mol Cell Cardiol. 2013;65:33–42.
   Google Scholar
• Baartscheer A, Hardziyenka M, Schumacher CA, et al. Chronic inhibition of the Na +/H +- exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol. 2008;154:1266–1275.
   Google Scholar
• Tomaselli GF, Marbán E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270–283.
   Google Scholar
• Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;2108–2117.
   Google Scholar
• Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20:1361–1366.
   Google Scholar
• Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. Internet]. 2017;104:298–310.
   Google Scholar
• Kang S, Verma S, Teng G, et al. Direct effect of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG OUTCOME. Abstract Can J Cardiol. 2017;33:S169.
   Google Scholar
• Patel VB, Shah S, Verma S, et al. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev. 2017;22:889–902.
   Google Scholar
• Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–37.
   Google Scholar
• Konstantinou-Tegou A, Kaloyianni M, Bourikas D, et al. The effect of leptin on Na+-H+ antiport of obese and normal subjects erythrocytes. Mol Cell Endocrinol. 2001;183:11–18.
   Google Scholar
• Teta D, Bevington A, Brown J, et al. Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent post-transcriptional mechanism. J Am Soc Nephrol. 2003;14:2248–2254.
   Google Scholar
• Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by amp-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018 Mar 27;8(1):5276.
   Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine.Internet]. 2017;20:137–149.
   Google Scholar
• Hawley SA, Ford RJ, Smith BK, et al. The Na +/glucose cotransporter inhibitor canagli fl ozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65:2784–2794.
   Google Scholar
• Ye Y, Jia X, Bajaj M, et al. Dapagliflozin attenuates Na(+)/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32:553–558.
   Google Scholar
• Halliday BP, Wassall R, Lota AS, et al. Articles withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. [Internet]. 2018;6736:1–13.
   Google Scholar